パーキンソン病治療薬の世界市場2016-2026...市場調査レポートについてご紹介

【英文タイトル】Parkinson’s Diseases: World Drug Industry and Market 2016-2026

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Report Overview
1.1 Overview of Findings: World Market Overview 2015 to 2026
1.2 Why You Should Read This Report
1.3 How This Report Delivers: Chapter Outlines
1.4 Main Questions Answered by This Analysis
1.5 Who is This Study For?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About visiongain

2. Introduction to Parkinson’s Disease and its Treatments
2.1 What Causes Parkinson’s?
2.2 Motor Symptoms of Parkinson’s Disease
2.2.1 Tremor: The First Sign of PD
2.2.2 Uncontrolled Muscle Contractions Cause Rigidity
2.2.3 Bradykinesia: The Most Characteristic Feature of Parkinson’s
2.2.4 Postural Instability Manifests as PD Progresses
2.3 Neuropsychiatric Symptoms are Common in PD Patients
2.3.1 Behavioural Deficits are Often the Most Widespread
2.3.2 Cognitive Impairment can Impede Daily Tasks
2.3.3 Autonomic Dysfunction: Another Common Occurrence
2.4 Other Symptoms Associated with Parkinson’s
2.5 Parkinson’s Disease: Diagnosis and Treatment
2.5.1 Diagnosis is Difficult
2.5.2 Treatment Options – Therapeutic Classes

3. Parkinson’s Disease: World Drugs Market, 2016-2026
3.1 Sales of the Overall World PD Drugs Market, 2015-2026
3.2 Parkinson’s Disease: Market Segmentation, 2015
3.3 Overall PD Drug Market: Commercial Drivers and Restraints
3.4 Dopaminergic Agents: Foundation of PD Treatment
3.4.1 Levodopa Therapy
3.4.2 Patent Expiries Affect the Market
3.4.3 New Levodopa Therapies on the Horizon
3.4.4 Dopaminergic Agents: Market Projections to 2026
3.5 Dopamine Receptor Agonists: The Leading Class in 2016
3.5.1 Dopamine Agonists: A Front Line Drug
3.5.2 Advantages over L-Dopa Therapy
3.5.3 Leading Drugs in the Segment
3.5.4 A Healthy R&D Pipeline
3.5.5 Dopamine Receptor Agonists: Market Projections, 2016-2026
3.6 Catechol-O-Methyl Transferase (COMT) Inhibitors: A Popular Choice of Treatment
3.6.1 Entacapone: The Leading Drug in this Segment
3.6.2 Commercial Scope for COMT Inhibitors
3.6.3 COMT Inhibitors: Market Projections, 2016-2026
3.7 Are Monoamine Oxidase–B (MAO-B) Inhibitors Better Than COMT?
3.7.1 MAO-B Inhibitor Therapeutics in the Market
3.7.2 New MAO-B Products in Development
3.7.3 MAO-B Inhibitors: Market Projections, 2016-2026
3.7.4 Other Therapeutic Options: A Growing Opportunity
3.7.5 Generic Erosion in the PD Market
3.7.6 A Broad and Diverse Pharmaceutical Segment
3.7.7 Other Non-medication PD Therapies
3.7.8 The Pipeline Offers Disease Modifying Potential
3.7.9 Other Mechanisms of Action: Market Projections, 2016-2026

4. Leading Companies in the PD Drug Market, 2016
4.1 PD: Novartis sales of Stalevo/Comtan
4.1.1 Market Forecast for Comtan/Stalevo, 2016-2026
4.2 Teva’s Azilect: Past, Present and Future
4.2.1 Market Forecast for Azilect, 2015-2026
4.3 UCB’s Leading Neupro Patch Drug
4.3.1 Market Forecast for Neupro, 2016-2026
4.4 Other Market Players

5. The Leading National Markets, 2016-2026
5.1 Regional Breakdown of the World PD Drug Market, 2016
5.2 The World PD Drug Market: Regional Forecasts to 2026
5.3 The PD Drug Market in the US: The Largest Single National Market
5.3.1 Market Projections for the US, 2015-2026
5.4 The PD Drug Market in the Five Leading European National Markets (EU5), 2016-2026
5.4.1 Market Projections for the EU5, 2016-2026
5.4.2 EU5 Breakdown by Country, 2016
5.4.3 Market Projection for EU5 Countries, Regional Breakdown
5.4.4 Germany: The Largest EU5 Market
5.4.5 France: Strong Healthcare System – What’s Possible There?
5.4.6 UK’s Spending Restrictions Affect the PD Drugs Market
5.4.7 Spain – What Effects Will Austerity Have on PD Drug Sales?
5.4.8 The PD Drug Market in Italy: Rising and Ageing Population
5.5 Japan has the Highest Proportion of Over-65s in the World
5.5.1 Predictions for Japanese PD Drug Market, 2016-2026
5.6 PD Drug Market in Emerging Countries: Brazil, Russia, India and China (BRIC)
5.6.1 Breakdown of BRIC Revenues by Country, 2016
5.6.2 Market Projections for BRIC Nations’ PD Drug Sales, 2016-2026
5.6.3 Brazil’s Rapid Growth of the Pharma Market – What’s the Future?
5.6.4 Russia’s Healthcare Market Gives Generic Sales Opportunities
5.6.5 India: Generic Manufacturers Seek to Dominate the PD Market
5.6.6 China’s Ageing Population Stimulates Sales of PD-Treating Medicines

6. Research and Development for Treating Parkinson’s Disease
6.1 New Mechanisms of Action in the Late-Stage R&D Pipeline
6.2 Growing Potential of Marketed Products: Phase IV Studies
6.3 Phase III Clinical Products Promising Potential in the PD market
6.3.1 IPX203 (Impax Laboratories): The New Generation of Levodopa
6.3.2 Newron’s Safinamide Expected Launch in 2020
6.3.3 Pimavanserin: A First-in-Class Treatment for Parkinson’s Disease Psychosis
6.3.4 Istradefylline: A Promising A(2a) Receptor Antagonist
6.3.5 Termination of Preladenant, APromising A(2a) Receptor Antagonist
6.3.6 Levodopa/Carbidopa Intestinal Gel (LCIG)
6.3.7 Can Opicapone Compete with Existing COMT Inhibitors
6.3.8 Pitolisant: Addressing an Unmet Need
6.3.9 Northera: Oral Precursor of Norepinephrine
6.3.10 Targin by Mundipharm
6.3.11 Nurelinfor Levodopa-Induced Dyskinesia
6.3.12 SYN-115/120: Superior to Istradefylline?
6.4 Phase II PD Pipeline: Overview
6.4.1 Glutamatergic Drugs: Main Target for Pipeline Candidates
6.4.2 Fipamezole: Another Promising A(2a) Receptor Antagonist
6.4.3 CVT-301: A Novel Intrapulmonary Approach
6.4.4 DM-1992: Can Compete with Levodopa Reformulations?
6.4.5 The Accordion Pill Carbidopa/Levodopa by Intec Pharma
6.4.6 Orient Addresses Sialorrhoea
6.4.7 NH004: Formulated with a Muco-Adhesive Property
6.4.8 VR040: A Reformulation of Apomorphine
6.4.9 AVP-923: A Novel Approach for LID-PD
6.4.10 PD Giant Orion, Develop a New Levodopa Drug, ODM-101
6.4.11 News for NeuroDerm’s Reformulations
6.5 Phase I and Pre-clinical PD Pipeline: Overview
6.5.1 Vernalis’ A(2a) Receptor Antagonist Drug in Phase Ib/IIa
6.5.2 Sanofi Collaborates with The Michael J. Fox Foundation
6.5.3 UCL Show Exenatide Potential in Parkinson’s
6.5.4 Titan Pharmaceuticals Develop a Novel Platform
6.6 Neuroprotective Drugs Offer Hope
6.6.1 Phytopharm and Cogane Development
6.6.2 The Potential of Dietary Supplements
6.6.3 GCase Enzymes: Amicus and Biogen Strike A Deal for Parkinson’s
6.6.4 Research Finds Ursodeoxycholic Acid (UDCA) A Potential Cure for Parkinson’s
6.6.5 PD Biomarkers: Potential for Revolutionising Diagnosis and Treatment
6.6.6 Antibody Targeting: The Coming of Age
6.7 Gene Therapy: Promising Research and Technology
6.7.1 ProSavin: Leading Gene Therapy Product
6.7.2 CERE-120 Promises Repair of Damaged Dopaminergic Neurons
6.7.3 AAV-hAADC-2: Another Gene Therapy Contender
6.8 Parthenogenesis (International Stem Cell Corporation): A Promising Outlook for PD Technology

7. Qualitative Analysis of the PD Drug Market, 2016
7.1 SWOT Analysis of the PD Market
7.1.1 Strengths and Weaknesses in the PD Drug Industry in 2016
7.1.2 Opportunities and Threats There from 2016 Onwards
7.2 STEP Analysis of the PD Market
7.2.1 Social Implication of Living with PD
7.2.2 Technological Developments on the Horizon
7.2.3 Economic Pressures: Healthcare Budgeting
7.2.4 Political Issues: Patent Challenges, Data Exclusivity and Regulatory Pathways

8. Research Interviews
8.1 Interview with Dr. Russell Kern (Executive VP, Chief Scientific Officer): International Stem Cell Corporation, California, US
8.1.1 The Overall PD Market
8.1.2 Current Understanding of Stem Cell Therapy
8.1.3 ISCO’s Novel PD Programme
8.1.4 The Potential of Immune-Matching
8.1.5 The Controversy Surrounding Stem Cell Research
8.1.6 The Potential for Parthenogenesis in PD and Other Applications
8.2 Professor Jian Feng PhD, Department of Physiology and Biophysics, University at Buffalo, the State University of New York
8.2.1 A possible Cure
8.2.2 Future Potential: Research

9. Conclusions from the Research and Analysis
9.1 The World PD Market: Predictions to 2026
9.2 Which Therapeutic Class will Dominate the Market in 2026?
9.3 Disease Modification: The Ultimate Goal
9.4 The Future of the Industry and Market for Parkinson’s Medicines


【レポート販売概要】

■ タイトル:パーキンソン病治療薬の世界市場2016-2026
■ 英文:Parkinson’s Diseases: World Drug Industry and Market 2016-2026
■ 発行日:2016年5月
■ 調査会社:visiongain
■ 商品コード:VGAIN60623
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。